ACRS
Aclaris Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$3.48
+6.10%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 90.97x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 4.11x
- Price / sales
- 62.33x
- Price / cash flow
- -8.25x
Enterprise value
- Enterprise value
- $420.7M
- EV / sales
- 51.19x
- EV / EBITDA
- -5.59x
- EV / EBIT
- -4.87x
- Market cap
- $512.3M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026